142 related articles for article (PubMed ID: 10340542)
1. Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L).
Lorenz MG; Kantor JA; Schlom J; Hodge JW
Hum Gene Ther; 1999 May; 10(7):1095-103. PubMed ID: 10340542
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine.
Kantor J; Irvine K; Abrams S; Kaufman H; DiPietro J; Schlom J
J Natl Cancer Inst; 1992 Jul; 84(14):1084-91. PubMed ID: 1619682
[TBL] [Abstract][Full Text] [Related]
3. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
4. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
5. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity.
Hodge JW; McLaughlin JP; Abrams SI; Shupert WL; Schlom J; Kantor JA
Cancer Res; 1995 Aug; 55(16):3598-603. PubMed ID: 7543017
[TBL] [Abstract][Full Text] [Related]
6. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
McLaughlin JP; Schlom J; Kantor JA; Greiner JW
Cancer Res; 1996 May; 56(10):2361-7. PubMed ID: 8625312
[TBL] [Abstract][Full Text] [Related]
7. Induction of anti-tumor immunity elicited by tumor cells expressing a murine LFA-3 analog via a recombinant vaccinia virus.
Lorenz MG; Kantor JA; Schlom J; Hodge JW
Hum Gene Ther; 1999 Mar; 10(4):623-31. PubMed ID: 10094205
[TBL] [Abstract][Full Text] [Related]
8. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
[TBL] [Abstract][Full Text] [Related]
9. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.
Hodge JW; McLaughlin JP; Kantor JA; Schlom J
Vaccine; 1997; 15(6-7):759-68. PubMed ID: 9178479
[TBL] [Abstract][Full Text] [Related]
10. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity.
McLaughlin JP; Abrams S; Kantor J; Dobrzanski MJ; Greenbaum J; Schlom J; Greiner JW
J Immunother; 1997 Nov; 20(6):449-59. PubMed ID: 9409450
[TBL] [Abstract][Full Text] [Related]
11. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.
Hodge JW; Abrams S; Schlom J; Kantor JA
Cancer Res; 1994 Nov; 54(21):5552-5. PubMed ID: 7522961
[TBL] [Abstract][Full Text] [Related]
12. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
[TBL] [Abstract][Full Text] [Related]
13. CD27-CD27 ligand/CD70 interactions enhance alloantigen-induced proliferation and cytolytic activity in CD8+ T lymphocytes.
Brown GR; Meek K; Nishioka Y; Thiele DL
J Immunol; 1995 Apr; 154(8):3686-95. PubMed ID: 7706711
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration.
Conry RM; Khazaeli MB; Saleh MN; Allen KO; Barlow DL; Moore SE; Craig D; Arani RB; Schlom J; LoBuglio AF
Clin Cancer Res; 1999 Sep; 5(9):2330-7. PubMed ID: 10499601
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells.
Couderc B; Zitvogel L; Douin-Echinard V; Djennane L; Tahara H; Favre G; Lotze MT; Robbins PD
Cancer Gene Ther; 1998; 5(3):163-75. PubMed ID: 9622100
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines.
Hodge JW; Schlom J
Cancer Res; 1999 Oct; 59(20):5106-11. PubMed ID: 10537283
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate.
Kantor J; Irvine K; Abrams S; Snoy P; Olsen R; Greiner J; Kaufman H; Eggensperger D; Schlom J
Cancer Res; 1992 Dec; 52(24):6917-25. PubMed ID: 1458480
[TBL] [Abstract][Full Text] [Related]
18. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
[TBL] [Abstract][Full Text] [Related]
19. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
[TBL] [Abstract][Full Text] [Related]
20. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
Grosenbach DW; Barrientos JC; Schlom J; Hodge JW
Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
